ALIVUS vs JAGSNPHARM: Stock Comparison
ALIVUS LIFE SCIENCES is the larger company by market capitalisation. ALIVUS LIFE SCIENCES shows a lower P/E, a higher ROE and a higher ROCE, while JAGSONPAL PHARMACEUTICALS shows a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ALIVUS leads 7; JAGSNPHARM leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ALIVUS | JAGSNPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ALIVUS | JAGSNPHARM |
|---|---|---|
| Live Price | ₹1,426.5 | ₹215.28 |
| Day Change | 2.08% | -3% |
| Volume | 6.81 L | 26,323 |
| 52-Week High | ₹1,493.8 | ₹264.5 |
| 52-Week Low | ₹819 | ₹155 |
| Distance from 52W High | -4.51% | -18.61% |
Valuation
| Metric | ALIVUS | JAGSNPHARM |
|---|---|---|
| Market Cap | ₹17,495 Cr | ₹1,430 Cr |
| P/E Ratio | 28.39x | 32.35x |
| P/B Ratio | 5.14x | 6.09x |
| EPS | ₹49.03 | ₹2 |
| Book Value | ₹271.02 | ₹41.95 |
| Dividend Yield | 0.36% | 1.8% |
Growth
| Metric | ALIVUS | JAGSNPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.1% | 9.6% |
| EPS Growth (TTM YoY) | 14.5% | 23.8% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | ALIVUS | JAGSNPHARM |
|---|---|---|
| ROE | 16.94% | 15.6% |
| ROCE | 17.13% | 16.48% |
| Net Margin | 22.05% | 15% |
| Operating Margin | 29.65% | 20.38% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | ALIVUS | JAGSNPHARM |
|---|---|---|
| Promoter Holding | 74.85%▼ 0.02 pp | 25.46%▼ 0.09 pp |
| FII Holding | 5.93%▲ 0.39 pp | 2.14%▼ 0.16 pp |
| DII Holding | 7.03%▼ 0.15 pp | 1.65%▲ 1.03 pp |
| Public Holding | 12.19%▼ 0.22 pp | 27.4%▼ 0.63 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ALIVUS LIFE SCIENCES and JAGSONPAL PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.